



(51) International Patent Classification:

A61K 38/22 (2006.01) A61K 38/16 (2006.01)
A61B 5/16 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2023/073587

(22) International Filing Date:

06 September 2023 (06.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/374,879 07 September 2022 (07.09.2022) US
63/476,355 20 December 2022 (20.12.2022) US

(71) Applicant: OXEIA BIOPHARMACEUTICALS, INC.

[US/US]; 9920 Pacific Heights Boulevard, Suite 150, San Diego, California 92121 (US).

(72) Inventors: BANSAL, Vishal; c/o OXEIA BIOPHARMA-

CEUTICALS, INC., 9920 Pacific Heights Boulevard, Suite 150, San Diego, California 92121 (US). SHAH, Kartik; c/o OXEIA BIOPHARMACEUTICALS, INC., 9920 Pacific Heights Boulevard, Suite 150, San Diego, California 92121 (US). WYAND, Michael; c/o OXEIA BIOPHAR-

MACEUTICALS, INC., 9920 Pacific Heights Boulevard, Suite 150, San Diego, California 92121 (US).

(74) Agent: MASSEY, Cory A.; MINTZ, LEVIN, COHN,

FERRIS, GLOVSKY & POPEO, P.C., One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF MILD TRAUMATIC BRAIN INJURY

FIG. 3A



(57) Abstract: Disclosed are methods for mitigating one or more debilitating symptoms of a mTBI for a patient diagnosed with mTBI, e.g. sustained mTBI. These methods comprise administering an effective amount of ghrelin or a variant thereof over multiple consecutive days after the diagnosis of a mTBI, e.g. sustained mTBI.

WO 2024/054875 A3

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

11 April 2024 (11.04.2024)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/073587

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(8) - INV. - A61K 38/22; A61B 5/16; A61K 38/16; A61P 25/00 (2023.01) ADD.		
CPC - INV. - A61P 25/00; A61B 5/16; A61K 38/22, 9/0019 (2023.08) ADD. - A61K 9/7023 (2023.08) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) See Search History document		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Search History document		
Electronic database consulted during the international search (name of database and, where practicable, search terms used) See Search History document		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2021/133844 A1 (OXEIA BIOPHARMACEUTICALS INC.) 01 July 2021 (01.07.2021) entire document	1-5, 21-24, 31-33, 43-45
Y	WO 2017/075535 A1 (OXEIA BIOPHARMACEUTICALS INC.) 04 May 2017 (04.05.2017) entire document	1-5, 21-24, 31-33
Y	WO 2016/040322 A1 (SAGE THERAPEUTICS INC.) 17 March 2016 (17.03.2016) entire document	32
Y	WO 2016/134215 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 25 August 2016 (25.08.2016) entire document	43-45, 50, 51
Y	WO 2016/048488 A1 (OXEIA BIOPHARMACEUTICALS INC.) 31 March 2016 (31.03.2016) entire document	50, 51
A	US 10,632,064 B2 (AFGIN PHARMA, LLC) 28 April 2020 (28.04.2020) entire document	1-5, 21-24, 31-33, 43-45, 50, 51
A	US 2020/0254073 A1 (BEYOND BARRIERS THERAPEUTICS INC.) 13 August 2020 (13.08.2020) entire document	1-5, 21-24, 31-33, 43-45, 50, 51
A	US 11,241,483 B2 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 08 February 2022 (08.02.2022) entire document	1-5, 21-24, 31-33, 43-45, 50, 51
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "D" document cited by the applicant in the international application "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 03 December 2023		Date of mailing of the international search report FEB 02 2024
Name and mailing address of the ISA/ Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300		Authorized officer Taina Matos Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/073587

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 6-20, 25-30, 34-42, 46-49, 52-58
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.